AR061728A1 - COMPOSITION FOR TREATMENT USING SELECTIVE COMPOUNDS ALFA-2-DELTA-1 - Google Patents
COMPOSITION FOR TREATMENT USING SELECTIVE COMPOUNDS ALFA-2-DELTA-1Info
- Publication number
- AR061728A1 AR061728A1 ARP070102894A ARP070102894A AR061728A1 AR 061728 A1 AR061728 A1 AR 061728A1 AR P070102894 A ARP070102894 A AR P070102894A AR P070102894 A ARP070102894 A AR P070102894A AR 061728 A1 AR061728 A1 AR 061728A1
- Authority
- AR
- Argentina
- Prior art keywords
- delta
- composition
- alpha
- ligand
- alfa
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composicion para tratar un trastorno o afeccion usando un ligando alfa-2-delta, como por ejemplo, ácido (3S,4R,5R)-3-amino-4,5-dimetil octanoico, con gran afinidad y selectividad para el subtipo de la subunidad alfa-2-delta-1del canal de calcio. La administracion del ligando selectivo alfa-2-delta-1, o una sal farmacéuticamente aceptable, a un mamífero, incluyendo un hombre, evita o reduce los efectos adversos en comparacion con la administracion de un ligando no selectivo alfa-2-delta. Reivindicacion 7: La composicion de acuerdo con la reivindicacion 1 caracterizada porque el trastorno o afeccion es seleccionado de dolor, fibromialgia, epilepsia, síndrome de piernas inquietas, sofocos, trastornos del humor y trastornos del sueno.A composition for treating a disorder or condition using an alpha-2-delta ligand, such as, for example, (3S, 4R, 5R) -3-amino-4,5-dimethyl octanoic acid, with high affinity and selectivity for the subtype of the alpha-2-delta-1 subunit of the calcium channel. The administration of the selective alpha-2-delta-1 ligand, or a pharmaceutically acceptable salt, to a mammal, including a man, avoids or reduces adverse effects compared to the administration of a non-selective alpha-2-delta ligand. Claim 7: The composition according to claim 1 characterized in that the disorder or condition is selected from pain, fibromyalgia, epilepsy, restless legs syndrome, hot flashes, mood disorders and sleep disorders.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81815406P | 2006-06-30 | 2006-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061728A1 true AR061728A1 (en) | 2008-09-17 |
Family
ID=38739992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102894A AR061728A1 (en) | 2006-06-30 | 2007-06-28 | COMPOSITION FOR TREATMENT USING SELECTIVE COMPOUNDS ALFA-2-DELTA-1 |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2008013555A (en) |
| AR (1) | AR061728A1 (en) |
| TW (1) | TW200819123A (en) |
| WO (1) | WO2008004067A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009059924A1 (en) | 2007-11-05 | 2009-05-14 | Unilever Plc | Process for manufacturing tea products |
| JP7320494B2 (en) * | 2017-05-26 | 2023-08-03 | ノバッセイ エスエー | Voltage-gated calcium channel auxiliary subunit α2δ and its uses |
| JPWO2021079887A1 (en) * | 2019-10-25 | 2021-04-29 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2303244C (en) * | 1997-10-27 | 2005-12-06 | Warner-Lambert Company | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents |
| CN1495160A (en) * | 1997-12-16 | 2004-05-12 | ��ʲ | I-substituted-1-aminomethyl-cycloalkane derivative (gabapentin analogs), its preparation and application for curing neuropathy |
| SK287399B6 (en) * | 1999-06-10 | 2010-08-09 | Warner-Lambert Company Llc | Mono- and disubstituted 3-propyl gamma-aminobutyric acids, their useful for production of medicament and pharmaceutical compositions comprising same |
| HN2000000224A (en) * | 1999-10-20 | 2001-04-11 | Warner Lambert Co | BICYCLE AMINO ACIDS AS PHARMACEUTICAL AGENTS |
| CZ20032764A3 (en) * | 2001-04-19 | 2004-04-14 | Warner-Lambert Company | Fusion bicyclic or tricyclic amino acids |
| NI200300043A (en) * | 2002-03-28 | 2003-11-05 | Warner Lambert Co | AMINO ACIDS WITH AFFINITY FOR THE PROTEIN a2DELTA. |
| GB0225379D0 (en) * | 2002-10-31 | 2002-12-11 | Pfizer Ltd | Therapeutic proline derivatives |
| CA2540208A1 (en) * | 2003-09-25 | 2005-04-07 | Warner-Lambert Company Llc | Amino acids with affinity for the alpha2delta-protein |
| WO2005102390A2 (en) * | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
| EP1774318A2 (en) * | 2004-07-13 | 2007-04-18 | The Regents of The University of California | Models and methods for nociception, pain transduction, and screening for analgesic compounds |
| WO2006100606A2 (en) * | 2005-03-24 | 2006-09-28 | Warner-Lambert Company Llc | Preparation of beta-amino acid precursors via indium (iii) mediated markovnikov addition and knoevenagel condensation |
-
2007
- 2007-06-28 AR ARP070102894A patent/AR061728A1/en not_active Application Discontinuation
- 2007-06-29 WO PCT/IB2007/001789 patent/WO2008004067A2/en active Application Filing
- 2007-06-29 TW TW096123873A patent/TW200819123A/en unknown
- 2007-06-29 JP JP2007171344A patent/JP2008013555A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008013555A (en) | 2008-01-24 |
| WO2008004067A3 (en) | 2009-01-29 |
| WO2008004067A2 (en) | 2008-01-10 |
| TW200819123A (en) | 2008-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201100896A1 (en) | COMPOSITION INTENDED FOR SUCKING NICOTINE FROM THE FATAL CAVITY WITH THE PURPOSE TO STOP SMOKING | |
| EA200970435A1 (en) | TREATMENT OF GENERAL DEVELOPMENT DISORDERS | |
| UY30686A1 (en) | "NICOTINIC ACETILCOLINE RECEPTOR, SELECTIVE SUBTIPE OF AMIDAS DE DIAZABICILOALCANOS" | |
| DK1970059T3 (en) | Calcium dobesilate drug for the treatment and prophylaxis of tendon disorders | |
| EA201270221A1 (en) | TREATMENT OF CROWN DISEASE WITH LACQUINIMODE | |
| CY1111478T1 (en) | Indication of Progesterone Dosage in the Treatment of Traumatic Brain Injury | |
| EA201170018A1 (en) | Razagilin to change the flow of Parkinson's disease | |
| EA200802412A1 (en) | THERAPEUTIC COMBINATIONS FOR SUPPORTING MEDICAL CONDITIONS | |
| MX2011011656A (en) | Use of pde7 inhibitors for the treatment of movement disorders. | |
| MX2009010450A (en) | The use of pde7 inhibitors for the treatment of movement disorders. | |
| AR070025A1 (en) | USE OF DERIVATIVES OF 1-AMINO-ALQUILCICLOHEXANO FOR THE TREATMENT OF COCLEAR TINNITUS AND PHARMACEUTICAL COMPOSITION | |
| UA110013C2 (en) | APPLICATION OF THE COMPOSITION FOR THE TREATMENT OF BALL-MARI-HERE AND THE RELATED DISORDERS | |
| MX2019003173A (en) | Combination therapy with controlled-release cnp agonists. | |
| MX2021005967A (en) | Purified forms of rofecoxib, methods of manufacture and use. | |
| RU2015109566A (en) | NEW EXTRACTS FROM CYNARA SCOLYMUS, COFFEA spp. AND OLEA EUROPAEA FOR THE TREATMENT OF A METABOLIC SYNDROME | |
| MX2022002597A (en) | Methods of treating epilepsy using the same. | |
| AR061728A1 (en) | COMPOSITION FOR TREATMENT USING SELECTIVE COMPOUNDS ALFA-2-DELTA-1 | |
| EA200970127A1 (en) | MODULATOR OF GLUCOCORTICOSTEROID RECEPTORS AND METHODS OF ITS APPLICATION | |
| IL307992A (en) | Isoxazoline parasiticide formulations and methodsfor treating blepharitis | |
| CO6400019A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES RACETAM AND CARNITINE AND PROCESS FOR PREPARATION | |
| BR112015012497A2 (en) | pharmaceutical combinations | |
| RU2010154623A (en) | Derivatives of 1-aminoalkylcyclohexane for the treatment of sleep disorders | |
| RU2010129409A (en) | METHOD FOR TREATING RABBIT PSOROPTOSIS AND CARNIVOR ANIMAL OTODEKTOSIS | |
| EA201170583A1 (en) | NEW COMPOSITION FOR THE TREATMENT OF ESSENTIAL THROMBOCYTEMIA | |
| MX2016014740A (en) | A method for treating movement disorders with befiradol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |